menu
    • menu
    [{"orgOrder":0,"company":"Cyprumed","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Peptide","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cyprumed","amount2":0.48999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.48999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Cyprumed \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Cyprumed \/ Merck & Co"}]

    Find Oncology Clinical Drug Pipeline Developments & Deals by Cyprumed

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cyprumed

                            Austria arrow
                            AACR Annual meeting
                            Not Confirmed

                            Cyprumed

                            Austria arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Merck & Co

                            Deal Size : $493.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Merck Links up with Cyprumed in $493M Oral Peptide Deal

                            Details : Under the licensing agreement, MSD will acquire global rights to Cyprumed's platform for developing oral formulations of its peptide therapies.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            April 15, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Merck & Co

                            Deal Size : $493.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth